Memorial Sloan Kettering Cancer Center: Adenocarcinoma trials

The registry lists 18 Adenocarcinoma studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 1 are open to participants now and 9 have results posted.

Phase 1 5Phase 2 12Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Tucatinib and Trastuzumab in People With Rectal CancerRecruitingNCT05672524Phase 2
• A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal PassagesCompletedNCT03274414Phase 2Results posted
• A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to ErlotinibCompletedNCT03076164Phase 1/2Results posted
• Nintedanib in Patients With Advanced Esophagogastric CancerCompletedNCT02234596Phase 2Results posted
• Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to ErlotinibCompletedNCT02155465Phase 1/2Results posted
• Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold MaterialCompletedNCT01970306Phase 2Results posted
• Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ AdenocarcinomaCompletedNCT00737438Phase 2Results posted
• Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to ErlotinibCompletedNCT00716456Phase 1/2Results posted
• Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction AdenocarcinomaCompletedNCT00515411Phase 2Results posted
• Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal AdenocarcinomaCompletedNCT00390416Phase 2Results posted
• A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction CancerCompletedNCT04161781
• Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the LiverWithdrawnNCT03069950Phase 2
• Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung AdenocarcinomasCompletedNCT02120807Phase 1
• Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for AdenocarcinomaCompletedNCT01491698Phase 3
• Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic AdenocarcinomaCompletedNCT01474564
• Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)CompletedNCT01393483
• Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate CancerCompletedNCT00911118Phase 1
• Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaCompletedNCT00074009Phase 2